Sebia, Paris, and Abingdon Health, York, UK, have entered into a multiyear, exclusive, global distribution agreement. The deal enables Sebia to add Abingdon Health’s Seralite-FLC Dual Kappa and Lambda serum lateral flow immunoassay to its worldwide offerings.
The financial terms of the agreement have not been disclosed.
Seralite-FLC is a new rapid test for the quantitative measurement of free kappa and free lambda light chains in blood. Serum free light chain (sFLC) testing is prescribed to help detect, diagnose, and monitor such plasma cell disorders as multiple myeloma, and to monitor the effectiveness of treatments. The test is aimed at clinical laboratories with a small- to medium-sized workload for sFLC test requests, as well as at clinical laboratories sending requests to referral laboratories.
The agreement with Abingdon Health will enable Sebia to provide a comprehensive offering for the diagnosis and monitoring of multiple myeloma and associated conditions, addressing the emerging demand from clinical labs for improving responsiveness in their daily routine and in patient care.
The Seralite-FLC assay was initially developed via a joint venture with Abingdon Health Ltd and the University of Birmingham.
Benoit Adelus, Sebia.
“Since its creation in 1967 Sebia has had a strong focus on myeloma. Its leadership position in this field comes from a continuous flow of innovation to help laboratories in their daily activities diagnosing and monitoring this pathology,” says Benoit Adelus, chairman and CEO of Sebia. “The partnership with Abingdon Health will give the opportunity for small- to mid-size labs around the world to perform the FLC test on a high-quality, simple device.”
Chris Yates, Abingdon Health.
“We are delighted to partner with Sebia in the global distribution of serum Seralite-FLC,” says Chris Yates, CEO of Abingdon Health. “Sebia’s global reach and market leadership in the provision of electrophoresis testing makes it the perfect partner to launch our new product worldwide. We believe the combination of Abingdon Health and Sebia’s products provides customers with the complete solution for the testing of multiple myeloma [in serum].”
Sebia plans to supervise the global launch of Seralite-FLC across all of the company’s sales channels. The commercial team at Abingdon Health will also support the campaign. Sebia will distribute the product worldwide, except in Belgium, the Netherlands, and Luxembourg.
For more information, visit Sebia at AACC booth 2411 and Abingdon Health at AACC booth 3838.
